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Fibroblast growth factor (FGF)-23 is probably the most
important regulator of serum phosphate and calcitriol
(1,25(OH)2D3) levels. It is secreted by osteocytes and
osteoblasts in response to oral phosphate loading or
increased serum 1,25(OH)2D3 levels. In human chronic kidney
disease (CKD), plasma FGF-23 appears to be a sensitive
biomarker of abnormal renal phosphate handling, as FGF-23
levels increase during early stages of kidney malfunction.
In humans and animals with CKD, elevated FGF-23 levels
increase fractional phosphate excretion, reduce serum
phosphate levels, and reduce 1a-hydroxylase activity, which
reduces 1,25(OH)2D3 formation thereby increasing
parathyroid hormone (PTH) secretion. FGF-23 thus has a key
adaptive role in maintaining normophosphatemia. Plasma
FGF-23 continues to increase as CKD progresses, increasing
by orders of magnitude in end-stage renal disease. At the
same time, responsiveness to FGF-23 declines as the number
of intact nephrons declines, which is associated with reduced
expression of Klotho, the co-receptor required for FGF-23
signaling. In late CKD, FGF-23 cannot reduce serum
phosphate levels, and abnormally high plasma FGF-23
concentrations appear to exert unwarranted off-target
effects, including left ventricular hypertrophy, faster CKD
progression, and premature mortality. Lowering serum
phosphate levels through the use of oral phosphate binders
and/or long-acting PTH agents may reduce FGF-23 levels
in early CKD stages, thereby limiting off-target effects,
which may improve patient outcomes.
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Phosphate is essential for many cellular functions. It is a
constituent of DNA, membrane lipids, high-energy phos-
phates, and second messengers, that is, inositol trisphosphate,
cyclic adenosine monophosphate (cAMP), and cyclic guano-
sine monophosphate, and protein phosphorylation is an
essential process, which helps regulate enzyme and receptor
activities. Because phosphate is scarce in nature, vertebrate
physiology has evolved to conserve phosphate through the
efﬁcient use of three sodium-dependent phosphate co-
transporters (NaPi-IIa, NaPi-IIb, and NaPi-IIc, also referred
to as NPT2a, NPT2b, and NPT2c) that are highly conserved
throughout vertebrate taxa, from ﬁsh
1 to humans.
2 Additional
molecules contributing to the regulation of phosphate homeo-
stasis include Pit2 and the 1a-hydroxylase, which allows the
formation of calcitriol (1,25(OH)2D3). Expression of these
proteins in the proximal renal tubules is regulated by serum
phosphate concentration and different hormonal systems. For
example, low serum phosphate levels induce NPT2b expres-
sion in the intestinal tract, thus enhancing absorption of this
mineral from the diet. In addition, low serum phosphate levels
induce NPT2a and NPT2c expression in the proximal tubules
of the kidney, thus maximizing the reabsorption of phosphate
and minimizing urinary losses of this mineral. The efﬁciency
of this latter process was strikingly demonstrated in a 1976
study, in which healthy human volunteers on a low-phosphate
diet (90mg/day) reduced their phosphate excretion consider-
ably, thereby avoiding profound hypophosphatemia.
2 In contrast
to the efﬁcient adaptation to hypophosphatemia, renal excretion
of excess phosphate is a more difﬁcult problem for human
physiology to solve.
The principal hormones that regulate renal phosphate
handling are parathyroid hormone (PTH), which is produced
by the parathyroid gland, and ﬁbroblast growth factor (FGF)-
23, which is produced by osteocytes and osteoblasts in bone.
In healthy individuals, increasing serum phosphate concen-
tration induces secretion of PTH and FGF-23. These two
phosphaturic hormones reduce expression of NPT2a and
NPT2c in the proximal renal tubules, thereby diminishing
phosphate reabsorption and increasing urinary phosphate
excretion.
3,4 PTH also increases the 1a-hydroxylase in the
kidney, thereby increasing 1,25(OH)2D3 production, thus
enhancing intestinal calcium and phosphate absorption.
Some evidence suggests that PTH induces expression and
secretion of FGF-23; FGF-23 in turn decreases 1,25(OH)2D3
production, which is an inhibitor of PTH production.
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production enhances the excretion of phosphate per
nephron, thereby restoring normophosphatemia. However,
it also reduces 1,25(OH)2D3 levels,
5 contributing to an
increase in PTH secretion, which appears to occur after
FGF-23 levels increase. This process disrupts the bone–-
kidney–parathyroid endocrine axis and eventually fails to
prevent the development of hyperphosphatemia as CKD
progresses. The resulting changes, constituting CKD-related
mineral and bone disorder (CKD-MBD), are a reﬂection of
the trade-offs postulated by Bricker’s
6 intact nephron
hypothesis: ‘If solute intake does not diminish as the number
of excretory units diminishes, the adaptive increase in
excretion rate per nephron may be accomplished only at
the expense of one or more abnormalities of the uremic state.’
This review will explore preclinical and clinical studies of the
role of FGF-23 in phosphate metabolism in CKD and the
contribution of FGF-23 to CKD-MBD.
RENAL REGULATION OF PHOSPHATE AND CALCIUM
HOMEOSTASIS
Role of PTH: lessons from familial
pseudohypoparathyroidism
NPT2a and NPT2c facilitate the efﬁcient reabsorption of phos-
phate in the proximal tubule; expression of both transporters
is regulated by PTH and FGF-23. The acute PTH-dependent
regulation of NPT2a and NPT2c expression is mediated pre-
dominantly through the cAMP and protein kinase A signaling
pathway.
4 The PTH-induced increase in urinary phosphate is
coupled to cAMP excretion from proximal tubules. Cyclic
AMP production requires Gsa, which appears to be derived in
this portion of the kidney predominantly, if not exclusively,
from the maternal allele, thereby potentially limiting the
maximal amount of Gsa protein that can be generated in this
tissue. As a consequence of this parent-speciﬁc expression of
Gsa in the proximal renal tubules, maternally inherited,
heterozygous GNAS mutations cause PTH resistance, that is,
pseudohyperparathyroidism.
7 Inactivating GNAS mutations
in those exons that encode Gsa cause pseudohypoparathy-
roidism type Ia, whereas microdeletions within or upstream of
GNAS cause pseudohypoparathyroidism type Ib and are asso-
ciated with GNAS methylation changes. The mechanism by
which cAMP is excreted into the urine remains unknown, but
is expected to involve a speciﬁc transporter that is expressed
in the proximal tubule. In the distal tubule, PTH diminishes
calcium excretion through cAMP/protein kinase A- and possibly
also through inositol trisphosphate/protein kinase C-dependent
actions on the function of calbindin-D and TRPV5. In contrast
to the ﬁndings in proximal tubular cells, Gsa is expressed in the
distal tubular cells from both parental alleles, and maternally
inherited GNAS mutations consequently leave the PTH-induced
regulation of calcium excretion intact.
Role of FGF-23: lessons from CKD
Similar to the actions of PTH, FGF-23 controls NPT2a and
NPT2c expression. FGF-23 is secreted by bone cells in
response to 1,25(OH)2D3, which increases the mRNA levels
encoding this phosphaturic hormone.
8 FGF-23 mediates its
action in the kidney through an FGF receptor (FGFR)/Klotho
complex to downregulate NPT2a and NPT2c expression in
the proximal tubules. However, it is uncertain whether FGF-
23 signals initially through receptors in the distal convoluted
tubule cells in which ERK phosphorylation occurs in
response to FGF-23.
9 These cells are adjacent to NPT2a-
expressing proximal tubular cells and it has therefore been
speculated that a paracrine signal from the distal to the
proximal tubules is required for decreasing NPT2a expres-
sion. Even small changes in plasma FGF-23 levels are
associated with signiﬁcant changes in urinary phosphate
excretion, as shown by the small increase in FGF-23 levels
after unilateral nephrectomy in healthy kidney donors, which
is associated with increased urinary phosphate excretion.
10
Besides its effect on tubular phosphate handling, FGF-23
reduces PTH secretion, and it inhibits 1a-hydroxylase leading
to a decrease in 1,25(OH)2D3 production, which contributes
to the development of hypocalcemia and leads to an increase
in PTH production.
11 The 1,25(OH)2D3 itself increases FGF-
23 production.
FGF-23 AND PHOSPHATE IN CKD
FGF-23 appears to be an important biomarker for an
abnormal regulation of phosphate homeostasis in CKD and
is likely to be involved in CKD-MBD pathophysiology. As
CKD progresses, plasma FGF-23 levels increase. This increase
occurs earlier and to a greater extent than observed for serum
phosphate; in late CKD, plasma FGF-23 levels can be elevated
by several orders of magnitude.
5,12 Findings in experimental
renal disease suggest that the FGF-23 increase also precedes
the increase in PTH levels.
11 In fact, bone biopsies of patients
with CKD have shown increased expression of FGF-23
already by CKD stage 2, along with a marked increase in
DMP1 protein (a negative regulator of FGF-23), which may
be improperly processed and could thus be inactive.
13
Furthermore, in a prospective study of patients with mild-
to-moderate CKD,
14 higher plasma FGF-23 levels were shown
to predict a more rapid progression toward end-stage renal
disease (ESRD); similarly elevated FGF-23 levels predict CKD
progression in patients with diabetic nephropathy.
15 In
addition, elevated FGF-23 levels are independently associated
with left ventricular hypertrophy in patients with CKD,
16 an
important ﬁnding because CKD-MBD, and particularly
hyperphosphatemia, worsen the cardiovascular prognosis in
CKD. Aortic calciﬁcation, a major reason for cardiovascular
morbidity, in hemodialysis recipients is independently
predicted by plasma FGF-23.
17
Phosphate is a major regulator of FGF-23 expression.
18
Dietary phosphate loading increases FGF-23 expression,
whereas phosphate depletion with binders decreases the
circulating levels of this hormone.
19 In mild CKD, FGF-23
seems to function as a protective factor, as it triggers adaptive
changes that maintain normophosphatemia. For example, in
animal models, FGF-23 protects against hyperphosphatemia
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1,25(OH)2D3 production; diminished 1,25(OH)2D3 levels
lead to hypocalcemia and thus to an increase in PTH levels,
which further enhances renal phosphate excretion.
11 The
importance of FGF-23 in mediating these effects is shown by
the effects of anti-FGF-23 antibodies in rats with experi-
mental CKD.
11 Animals with early CKD that were treated
with anti-FGF-23 antibodies showed an increase in
1,25(OH)2D3 levels, a normalization of serum calcium levels,
and a decrease in PTH levels. Furthermore, fractional
phosphate excretion decreased because of inactivation of
FGF-23 resulting in hyperphosphatemia.
As CKD progresses, elevated FGF-23 levels are no longer
able to enhance urinary phosphate excretion, thus leading to
the development of hyperphosphatemia. This may be partly
related to declining Klotho expression and a reduction in
functional nephrons. When patients require treatment by
dialysis, the levels of immunoreactive FGF-23 can be
markedly elevated (Figure 1).
20 However, unlike the appear-
ance of large amounts of C-terminal PTH fragments, most of
which are biologically inactive, practically all of the circulat-
ing FGF-23 present in patients with ESRD is intact and
biologically active. This conclusion is based on observations
with a reporter-cell assay (human embryonic kidney cells
expressing Klotho and a luciferase reporter expressed under
the control of the EGR-1 promoter) designed to quantify
biologically active FGF-23, which demonstrated excellent
correlation with immunoreactive measurement of FGF-23.
The immunometric assays used for these measurements
quantify the intact FGF-23 molecule alone (Kainos assay)
or the intact protein along with a C-terminal fragment
(Immutopics assay).
21,22 Consistent with the excellent correla-
tion between bioactive and immunoreactive FGF23, Western
blot analyses of plasma FGF-23 from dialysis patients showed
that most of the circulating FGF-23 is intact.
21 Thus, with
CKD progression, the excess of biologically active FGF-23,
which is thought to occur in response to hyperphosphatemia,
ceases to be protective and may lead to pathological off-target
effects that potentially contribute to the increase in mortality
as FGF-23 increases in patients with ESRD
23,24 (Figure 2).
Interventions that lower serum phosphate, such as oral
phosphate binders to prevent intestinal absorption or
possibly long-acting PTH analogs that reduce NPT2a or
NPT2c expression, may help prevent CKD-related FGF-23
increases (Figure 3). For example, two recently reported,
long-acting PTH analogs (M-PTH(1-28) and Trp1-M-
PTH(1-28)) were found to efﬁciently reduce NPT2a expres-
sion in proximal tubules, leading to sustained hypopho-
sphatemia in wild-type mice.
25 Targeting the proximal
tubules with long-acting PTH agents in early CKD may
add to the effects of phosphate binders in normalizing serum
phosphate levels and may help avoid an increase in FGF-23,
unless PTH has a role in the synthesis and/or secretion of
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Figure 1|Spectrum of serum fibroblast growth factor (FGF)-23
levels in early chronic kidney disease and end-stage renal
disease (ESRD) as compared with the normal condition and
with different disorders affecting FGF-23. ADHR, autosomal
dominant hypophosphatemic rickets; ARHP, autosomal recessive
hypophosphatemia; TIO, tumor-induced osteomalacia; XLH, X-linked
hypophosphatemia. Adapted with permission from Isakova et al.
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Figure 2|Mortality in patients with end-stage renal disease
(ESRD) receiving hemodialysis in relationship to quartiles of
serum fibroblast growth factor (FGF)-23 concentration at
initiation of dialysis. R, reference. Reproduced with permission
from Gutie ´rrez et al.
23 Copyright The Massachusetts Medical
Society.
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Figure 3|‘Trade-off hypothesis’ revisited. Involvement of
fibroblast growth factor (FGF)-23 in end-stage renal disease
(ESRD) pathology, reflecting potentially adverse effects of
increased secretion of this phosphaturic hormone, which helps
normalize phosphate homeostasis but contributes to the
development of secondary hyperparathyroidism. PTH, parathyroid
hormone.
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transient hyperphosphatemia in CKD may thus prevent an
increase in FGF-23 and the hormone’s putative off-target
effects in CKD-MBD. In support of this conclusion, a recent
post hoc analysis of a randomized clinical trial has shown that
treatment with phosphate binders can markedly decrease
FGF-23 levels in patients undergoing hemodialysis.
26
CONCLUSIONS
FGF-23 is a bone-generated major regulator of phosphate
homeostasis, which appears to be an important biomarker of
phosphate homeostasis in patients with CKD. Plasma FGF-23
concentrations begin to increase early in CKD, with increases
by orders of magnitude by the time patients reach ESRD.
Increasing FGF-23 levels are independently associated with
left ventricular hypertrophy, CKD progression, and mortality,
possibly through off-target actions. Lowering serum phos-
phate levels through the use of phosphate binders may lower
FGF-23 levels. Further research is needed to show whether
lowering FGF-23 levels improves outcomes in patients
with CKD.
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